Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prognostic Significance of CD7+CD56+ Phenotype and Chromosome 5 Abnormalities for Acute Myeloid Leukemia M0


Myeloid/natural killer (NK) cell precursor acute leukemia is an entity of acute leukemia characterized by poor prognosis and a CD7+CD56+ myeloid antigen+ phenotype without light-microscopic myeloperoxidase reactivity. This disease shares several clinical characteristics with acute myeloid leukemia (AML) M0. To clarify the relationship between these 2 leukemias, we analyzed 105 cases of AML M0. Among them, 17 were CD7+ and CD56+, 77 were negative for either antigen, and 11 could not be determined. CD7+CD56+ AML M0 showed onset at significantly lower patient age (median 46 versus 63 years,P =.004). The disease localization and the hematological manifestations were significantly different: CD7+CD56+ AML showed more frequent extramedullary involvement, fewer circulating leukemic blasts, less anemia, and less thrombocytopenia than did AML M0. The cytogenetic aberrations were also unique, because no 5q abnormalities were found in CD7+CD56+ M0. The prognosis of CD7+CD56+ M0 was poor in patients younger than 46 years(P =.03). Multivariate analysis showed that the CD7+CD56+ phenotype was a significant prognostic factor for AML M0, as well as age, circulating blast percentage, and chromosome 5 abnormalities. These findings suggest that AML M0 consists of heterogeneous subgroups to be managed separately, and CD7+CD56+ M0 constitutes a distinct subtype of AMLM0.

This is a preview of subscription content, log in to check access.


  1. 1.

    Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the clas- sification of the acute leukaemias. French-American-British (FAB) co-operative group.Br J Haematol. 1976;33:451–458.

  2. 2.

    Foon KA,Todd RF III. Immunologic classification of leukemia and lymphoma.Blood. 1986;68:1–31.

  3. 3.

    Neame PB, Soamboonsrup P, Browman GP, et al. Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML.Blood. 1986;68:1355–1362.

  4. 4.

    Bene MC, Castoldi G, Knapp W, et al. Proposals for the immuno- logical classification of acute leukemias.Leukemia. 1995;9: 1783–1786.

  5. 5.

    Bennett JM, Catovsky D, Daniel M-T, et al. Criteria for the diag- nosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.Ann Int Med. 1985;103:460–462.

  6. 6.

    Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the recognition of minimally differentiated acute myeloid leukemia (AML-M0).BrJ Haematol. 1991;78:325–329.

  7. 7.

    Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/ natural killer cell precursor acute leukemia: a distinct hematolym- phoid disease entity.Blood. 1997;90:2417–2428.

  8. 8.

    Nagai M, Bandoh S, Tasaka T, et al. Secondary myeloid/natural killer cell precursor acute leukemia following essential thrombocy- topenia.Hum Pathol. 1999;30:868–871.

  9. 9.

    Inaba T, Shimazaki C, Sumikuma T, et al. Clinicopathological fea- tures of myeloid/natural killer (NK) cell precursor acute leukemia.Leuk Res. 2001;25:109–113.

  10. 10.

    Handa H, Motohashi S, Isozumi K, Komatsumoto S, Nara M. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.Acta Haemato- logica. 2002;108:47–52.

  11. 11.

    Ikewaki J, Otsuka E, Satou J, et al. Myeloid/natural killer cell pre- cursor acute leukaemia with minor bcr/abl mRNA transcript.Br J Haematol. 2002;118:684–685.

  12. 12.

    Tezuka K, Nakayama H, Honda K, et al. Treatment of a child with myeloid/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation.Int J Hematol. 2002;75: 201–206.

  13. 13.

    Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA. Minimally dif- ferentiated acute nonlymphocytic leukemia: a distinct entity.Blood. 1987;70:1400–1406.

  14. 14.

    Cadwell FJ, Burns CP, Dick FR, et al. Minimally differentiated acute leukemia.Leuk Res. 1993;17:199–208.

  15. 15.

    Yokose N, Ogata K, Ito T, et al. Chemotherapy for minimally dif- ferentiated acute myeloid leukemia (AML M0): a report of five cases and review of the literature.Ann Hematol. 1993;66:67–70.

  16. 16.

    Sempere A, Jarque I, Guinot M, et al. Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.Leuk Lymphoma. 1993;12:103–108.

  17. 17.

    Stasi R, Del Poeta G, Venditti A, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0).Blood. 1994;83:1619–1625.

  18. 18.

    Venditti A, Del Poeta G, Stasi R, et al. Minimally differentiated acute myeloid leukemia (AML-M0): cytochemical,immunopheno- typic and cytogenetic analysis of 19 cases.Br J Haematol. 1994;88: 784–793.

  19. 19.

    Tsunoda S, Yoshida M. Diagnosis and treatment of acute undiffer- entiated leukemia and AML M0.Rinsho Ketsueki. 1994;35:238–244.

  20. 20.

    Cuneo A, Ferrant A, Michaux JL, et al. Cytogenetic profile of min- imally differentiated (FAB M0) acute myeloid leukemia: correla- tion with clinicobiologic findings.Blood. 1995;85:3688–3694.

  21. 21.

    Venditti A, Del Poeta G, Buccisano F, et al. Minimally differenti- ated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes.Blood. 1997;89: 621–629.

  22. 22.

    Cohen PL, Hoyer JD, Kurtin PJ, Dewald GW, Hanson CA. Acute myeloid leukemia with minimal differentiation.Am J Clin Pathol. 1998;109:32–38.

  23. 23.

    Villamor N, Zarco M-A, Rozman M, Ribera J-M, Feliu E, Montser- rat E. Acute myeloblastic leukemia with minimal myeloid differ- entiation: phenotypical and ultrastructural characteristics.Leukemia. 1998;12:1081–1075.

  24. 24.

    Huang S-Y, Tang J-L, Jou S-T, et al. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.Leukemia. 1999; 13:1506–1512.

  25. 25.

    Cascavilla N, Milillo L, Díarena G, et al. Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases.Leuk Lymphoma. 2000;37:105–113.

  26. 26.

    Kotylo PK, Seo I-S, Smith FO, et al. Flow cytometric immunophe- notypic characterization of pediatric and adult minimally differen- tiated acute myeloid leukemia (AML M0).Am J Clin Pathol. 2000; 113:193–200.

  27. 27.

    Kaleem Z, White G. Diagnostic criteria for minimally differenti- ated acute myeloid leukemia (AML-M0): evaluation and a proposal.Am J Clin Pathol. 2001;115:876–884.

  28. 28.

    Béné M-C, Bernier M, Casasnovas RO, et al. Acute myeloid leukemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.Br J Haematol. 2001;113:737–745.

  29. 29.

    Mitelman F, ed.ISCN 1991: Guidelines for Cancer Genetics: Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1992.

  30. 30.

    Sandberg AA. Cytogenetic features of special hematologic disor- ders, including some aspects of acute leukemia. In: Sandberg AA, ed.The Chromosomes in Human Cancer and Leukemia. 2nd ed. New York: Elsevier; 1990:374.

  31. 31.

    Iwata H, Kami M, Kishi Y, et al. Limitation of the diagnostic crite- ria for minimally differentiated acute myeloid leukemia (AML M0).Leukemia. 2000;14:2013–2014.

  32. 32.

    Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score.Blood. 2000;96:870–877.

  33. 33.

    Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multi- center study for treatment of acute lymphoblastic leukemia in adults.Blood. 1988;71:123–131.

  34. 34.

    Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lym- phoblastic leukemia: the memorial hospital experience since 1969.J Clin Oncol. 1988;6:1014–1030.

  35. 35.

    Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia: a com- prehensive review with emphasis on biology and therapy.Cancer. 1995;76:2393–2417.

  36. 36.

    Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophe- notype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8364.Blood. 1999;93: 3931–3939.

  37. 37.

    Paietta E, Neuberg D, Richards S, et al. Eastern Cooperative Oncology Group. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phe- notypic and genotypic heterogeneity.Am J Hematol. 2001;66: 189–196.

  38. 38.

    Iizuka Y, Aiso M, Oshimi K, et al. Myeloblastoma formation in acute myeloid leukemia.Leuk Res. 1992;16:665–671.

  39. 39.

    Seymour JF, Pierce SA, Kantarjian HM, Keating MI, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).Leukemia. 1994;8:823–826.

  40. 40.

    Byrd JC, Weiss RB. Recurrent granulocytic sarcoma: an unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule.Cancer. 1994;73:2107–2112.

  41. 41.

    Thomas X, Vila L, Campos L, Sabido O, Archimbaud E. Expression N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome.Leuk Lymphoma. 1995;19:295–300.

  42. 42.

    Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22;q22).Blood. 1997;90:1643–1648.

  43. 43.

    Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?J Clin Oncol. 1999;17:293–297.

  44. 44.

    Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indi- cator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.J Clin Oncol. 2000;18:1295–1300.

  45. 45.

    Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V Jr, Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy.Am J Surg Pathol. 1992;16:236–245.

  46. 46.

    Inhorn RC, Aster JC, Roach SA, et al. A syndrome of lymphoblas- tic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clini- copathologic entity.Blood. 1995;85:1881–1887.

  47. 47.

    Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype.Blood. 2000;96: 2993–3000.

  48. 48.

    Fernandez LA, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult and establishment of an NK cell line.Blood. 1986;67:925–930.

  49. 49.

    Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-gly- coprotein/ MDR1 by nasal T-cell lymphoma cells.Cancer. 1995;76: 2351–2356.

  50. 50.

    Kwong YL, Chan ACL, Liang R, Chiang AKS, Chim CS, Chan TK. CD56+ NK lymphomas: clinicopathological features and prognosis.BrJ Haematol. 1997;97:821–829.

  51. 51.

    Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.J Clin Oncol. 1998;16:70–77.

  52. 52.

    Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia.Leuk Res. 1999;23:615–624.

  53. 53.

    Mraz-Gernhard S, Natkunam Y, Hoppe RT, LeBoit P, Kohler S, Kim YH. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course.J Clin Oncol. 2001;19:2179–2188.

Download references

Author information

Correspondence to Ritsuro Suzuki or Makoto Murata or Masahiro Kami or Shigeki Ohtake or Norio Asou or Yoshihisa Kodera or Masao Tomonaga or Yasufumi Masaki or Shuya Kusumoto or Jin Takeuchi or Shin Matsuda or Hisamaru Hirai or Seiichi Yorimitsu or Nobuyuki Hamajima or Masao Seto or Masanori Shimoyama or Ryuzo Ohno or Yasuo Morishima or Shigeo Nakamura.

About this article

Cite this article

Suzuki, R., Murata, M., Kami, M. et al. Prognostic Significance of CD7+CD56+ Phenotype and Chromosome 5 Abnormalities for Acute Myeloid Leukemia M0. Int J Hematol 77, 482–489 (2003).

Download citation

Key words

  • AML M0
  • Myeloid/NK cell precursor acute leukemia
  • CD7
  • CD56
  • Prognosis